As we wait for ATX-LPA inhibitors to move from preclinical into clinical trials, further investigation is needed regarding this complex signaling pathway to achieve more efficient therapeutics in cancer and other ATX-LPA axis-related pathologies. This evidence concerns the gene LPA and cancer.